Gastroenterology
Volume 136, Issue 5 , Pages 1601-1608 , May 2009

Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes

  • Hashem B. El–Serag

      Affiliations

    • Sections of Gastroenterology and Health Services Research at the Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas
    • Corresponding Author InformationReprint requests Address requests for reprints to: Hashem B. El–Serag, MD, MPH, The Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, Texas 77030. fax: (713) 748-7359
    • ,
  • Michael L. Johnson

      Affiliations

    • Department of Clinical Sciences and Administration, University of Houston, College of Pharmacy, Houston, Texas
    • ,
  • Christine Hachem

      Affiliations

    • Sections of Gastroenterology and Health Services Research at the Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas
    • ,
  • Robert O. Morgana

      Affiliations

    • Sections of Gastroenterology and Health Services Research at the Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas

Received 2 June 2008 ,Accepted 26 January 2009.

References 

  1. Blanco-Colio LM, Villa A, Ortego M, et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 2002;161:17–26
  2. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90:635–637
  3. Shibata MA, Kavanaugh C, Shibata E, et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis. 2003;24:453–459
  4. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508–519
  5. Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999;96:7797–7802
  6. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576
  7. Huether A, Hopfner M, Baradari V, et al. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005;70:1568–1578
  8. Sutter AP, Maaser K, Hopfner M, et al. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors (Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor). J Hepatol. 2005;43:808–816
  9. Taras D, Blanc JF, Rullier A, et al. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol. 2007;46:69–76
  10. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma (A randomized controlled trial). Br J Cancer. 2001;84:886–891
  11. Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol. 2008;
  12. Ikeda M, Abe K, Yamada M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44:117–125
  13. Ye J, Wang C, Sumpter R, et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A. 2003;100:15865–15870
  14. MacDonald JS, Gerson RJ, Kornbrust DJ, et al. Preclinical evaluation of lovastatin. Am J Cardiol. 1988;62:16J–27J
  15. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55–60
  16. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol. 2000;86:257–262
  17. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771–777
  18. Bjerre LM, LeLorier J. Do statins cause cancer? (A meta-analysis of large randomized clinical trials). Am J Med. 2001;110:716–723
  19. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003;7:415–433
  20. Prentice RL, Kalbfleisch JD, Peterson AV, et al. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541–554
  21. Morgan RO, Johnson ML. Individual-level factors affecting enrollment in Medicare+choice plans and use of VA medical care by Medicare enrolled white, African American and Hispanic veterans. Final report for IIR 20-052: Medicare HMO enrollment and VA use by minority and low-income veterans. Department of Veterans Affairs, HSR&D Service; 2004;
  22. Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol. 2004;57:1223–1231
  23. Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci U S A. 2002;99:8301–8305
  24. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712–1719
  25. Mallat A, Preaux AM, Blazejewski S, et al. Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology. 1994;20:1589–1594
  26. Rombouts K, Kisanga E, Hellemans K, et al. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol. 2003;38:564–572
  27. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999;37:846–857
  28. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–116

 Conflicts of interest The authorsdisclose no conflicts.

 Funding This research was supported in part by the Department of Veterans Affairs, Health Services Research and Development Service (IIR 02-081), and by a grant from the American College of Gastroenterology. Dr El–Serag is supported by a National Institutes of Health grant (K24DK078154-03).

PII: S0016-5085(09)00157-7

doi: 10.1053/j.gastro.2009.01.053

Gastroenterology
Volume 136, Issue 5 , Pages 1601-1608 , May 2009

Article Tools